• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Antibacterial activity and pharmacokinetics of nitroimidazoles. A review.

作者信息

Bergan T

出版信息

Scand J Infect Dis Suppl. 1985;46:64-71.

PMID:3865352
Abstract

The antibacterial activity of metronidazole and tinidazole are comparable. The former is subject to biotransformation with the production of both hydroxy-metronidazole and acetylmetronidazole. The hydroxylated moiety has an antibacterial activity and may act either synergistically or additively in combination with metronidazole, thus enhancing the therapeutic activity of the latter. Metronidazole and tinidazole may be given both orally and parenterally. The bioavailability of oral doses of metronidazole is 88-95%, that of tinidazole 90%. Rectal suppositories have a bioavailability of 60-70%. The serum half-life of metronidazole is 6-10 hours, that of hydroxy-metronidazole 9.5-19 hours, and that of tinidazole 9-14 hours. The half-life may be longer in patients who have undergone colorectal surgery. Renal failure enhances the elimination of hydroxy-metronidazole and acetyl-metronidazole, whereas the consequences for unchanged metronidazole are negligible. The effect of reduced renal function on tinidazole is unclear. The extravascular penetration of metronidazole and tinidazole are similar. A single prophylactic intravenous dose of 1500 mg of either drug causes prolonged antibacterial effects which would last 36-48 hours for both drugs.

摘要

相似文献

1
Antibacterial activity and pharmacokinetics of nitroimidazoles. A review.
Scand J Infect Dis Suppl. 1985;46:64-71.
2
In vitro interactions between metronidazole or tinidazole and ampicillin, doxycycline and co-trimoxazole on the effect against anaerobic bacteria.
Scand J Gastroenterol Suppl. 1984;91:95-101.
3
The pharmacokinetics of one single preoperative dose of metronidazole or tinidazole.
Scand J Gastroenterol Suppl. 1984;90:89-96.
4
Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses.单次大剂量口服后替硝唑和甲硝唑在女性体内的药代动力学
Br J Vener Dis. 1975 Feb;51(1):51-3. doi: 10.1136/sti.51.1.51.
5
Tinidazole as a prophylactic agent in hysterectomy: a clinical and pharmacokinetic comparison with metronidazole.替硝唑作为子宫切除术的预防用药:与甲硝唑的临床及药代动力学比较
Pharmatherapeutica. 1981;3(1):67-70.
6
[Anaerobic effect of tinidazol compared with metronidazol, ornidazol, cefoxitin and lamoxactam].[替硝唑与甲硝唑、奥硝唑、头孢西丁和拉莫三嗪的厌氧作用比较]
Immun Infekt. 1983 Jun;11(4):143-7.
7
Comparative pharmacokinetics of metronidazole and tinidazole used as single dose prophylactic agents.甲硝唑和替硝唑作为单剂量预防剂的比较药代动力学
Scand J Gastroenterol Suppl. 1984;90:97-106.
8
[Efficacy of tinidazole against anaerobes in comparison with metronidazole, ornidazole, cefoxitin and lamoxactam].[替硝唑与甲硝唑、奥硝唑、头孢西丁和拉莫三嗪相比对厌氧菌的疗效]
Immun Infekt. 1983 Jun;11(4):143-7.
9
In vitro susceptibility of anaerobic bacteria to nitroimidazoles.厌氧菌对硝基咪唑类药物的体外敏感性
Scand J Infect Dis Suppl. 1981;26:42-5.
10
["In vitro" susceptibility of some aerobic and anaerobic bacteria to three 5-nitro-imidazole derivatives: metronidazole, ornidazole and tinidazole (author's transl)].某些需氧菌和厌氧菌对三种5-硝基咪唑衍生物:甲硝唑、奥硝唑和替硝唑的“体外”敏感性(作者译)
Ann Microbiol (Paris). 1980 Jan-Feb;131(1):45-59.

引用本文的文献

1
Roles of efflux pumps and nitroreductases in metronidazole-resistant Trichomonas vaginalis.外排泵和硝基还原酶在甲硝唑耐药阴道毛滴虫中的作用。
Parasitol Res. 2025 Feb 12;124(2):21. doi: 10.1007/s00436-025-08463-7.
2
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.艰难梭菌感染治疗方法的研究进展:临床和药物化学综述。
Curr Top Med Chem. 2014;14(1):152-75. doi: 10.2174/1568026613666131113154753.
3
Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study.
多种耐药调节剂联合卡铂治疗耐药性恶性肿瘤:一项试点研究。
Invest New Drugs. 1997;15(4):267-77. doi: 10.1023/a:1005993705237.